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Abstract. Since plasmid DNA (pDNA) is unstable in solution, lyophilisation can be used to increase
product shelf life. To prevent stress on pDNA molecules during lyophilisation, cryo- and lyoprotectants
have to be added to the formulation. This study assessed the effect of disaccharides on naked pDNA
stability after lyophilisation using accelerated stability studies. Naked pDNA was lyophilised with
sucrose, trehalose, maltose or lactose in an excipient/DNA w/w ratio of 20. To one part of the vials extra
residual moisture was introduced by placing the vials half opened in a 25°C/60% RH climate chamber,
before placing all vials in climate chambers (25°C/60% RH and 40°C/75% RH) for stability studies. An
ex vivo human skin model was used to assess the effect of disaccharides on transfection efﬁciency.
Lyophilisation resulted in amorphous cakes for all disaccharides with a residual water content of 0.8% w/w.
Storage at 40°C/75% RH resulted in decreasing supercoiled (SC) purity levels (sucrose and trehalose
maintained approximately 80% SC purity), but not in physical collapse. The addition of residual moisture
(values between 7.5% and 10% w/w) resulted in rapid collapse except for trehalose and decreasing SC
purity for all formulations. In a separate experiment disaccharide formulation solutions show a slight but
signiﬁcant reduction (<3% with sucrose and maltose) in transfection efﬁciency when compared to pDNA
dissolved in water. We demonstrate that disaccharides, like sucrose and trehalose, are effective
lyoprotectants for naked pDNA.
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INTRODUCTION
Gene therapy using plasmid DNA (pDNA) for vaccina-
tion against cancer requires DNA-based pharmaceuticals
which can be stored, shipped and applied even under critical
environmental conditions. The physical and chemical stability
of pDNA is inﬂuenced by the formulation (e.g., excipients,
dosage form) and storage conditions (1–3). During storage of
the supercoiled (SC) pDNA, the topoisoform associated with
the highest transfection efﬁciency, is mainly converted to open
circular (OC) pDNA (single strand breaks) and linear pDNA
(double stranded break; 3). The SC topology (and transfection
efﬁciency) can be maintained when pDNA solutions are stored
at −80°C (3). However, for clinical practise it is desirable that
the product can be stored at higher temperatures, especially
when shipping for instance to developing countries. Depending
on the excipients in the liquid formulation, solutions can be
stable for up to 12 months when stored at 4°C (2,3) and for at
least 3 years when stored at −20°C (2). To prolong the shelf life
of pDNA formulations at higher temperatures, lyophilisation
can be used. An additional advantage of lyophilisation is that it
is possible to concentrate solutions by reconstitution of the
dried product with a smaller volume (4). Lyophilisation may
increase the stability of pDNA under long-term storage, but
may also cause some damage during the subsequent freezing
and drying steps of the lyophilisation process (5–7). Lyophilisa-
tion causes the removal of the hydration sphere around a
molecule (5). It has been reported with X-ray diffraction,
infrared and ultraviolet spectroscopy that hydration water is
necessary for maintaining the structural integrity of the DNA
molecule. In the absence of water, the ordered conformation is
lost and base stacking is destroyed (8). Lyophilisation without
protecting agent results in signiﬁcant loss of plasmid DNA
activity (up to 75%), due to loss of hydration water and
subsequent changes in conformation (4,5). Agents that can
substitute for non-freezable water, such as sugars, can demon-
strate cryo- and lyoprotective properties for DNA and other
molecules during lyophilisation (5,9). In the pDNA ﬁeld
extensive research on the stabilisation of non-viral DNA
vectors, i.e., pDNA complexed with lipids or polymers, has
been conducted (4,9–14). In this respect, different types of
sugars have been evaluated for their cryo- and lyoprotective
properties. Disaccharides and oligosaccharides like dextrans or
inulins or combinations of both have proven most efﬁcient
(4,7,9–12,15–17).Focusofthesestudies,however,wasprimarily
thephysicalstabilisationofthenon-viralpDNAvectorparticles
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ofourknowledgefewifanystudieshavebeenconductedonthe
stabilising effect of disaccharides on naked pDNA upon
lyophilisation and storage under various conditions. Disaccha-
rides, like sucrose, trehalose, maltose and lactose have proven
excellent stabilisers for proteins since they are able to form
hydrogen bonds (18,19) also sucrose has been shown to work
via preferential exclusion, therefore favouring the shape with
the smallest surface area (20). Possibly these hydroxyl groups
could also stabilise pDNA, since pDNA is also able to form
hydrogen bonds. In fact, it has been shown that hydrogen
bonding excipients are effective against moisture-induced
aggregation of DNA in a solid state (21). In this study, we
assessed the protective properties of different disaccharides on
naked DNA by means of accelerated stability studies using
elevatedtemperaturesand increasedresidualmoisture content.
Theinteractionofwatervapourwithcrystallineandamorphous
solids can play an important role in the physical form and the
potential for physical transformation such as cake softening or
collapse. The sorption of water vapour depends on the afﬁnity
of the material for water, the physical state of the solid, relative
humidity, temperature and time (22). As template, we used the
novel in-house developed plasmid DNA vaccine encoding
recombinant MART-1 and tetanus toxin fragment-c (pDER-
MATT). pDERMATT is currently in a phase I clinical study in
advanced stage melanoma patients investigating its toxicity
upon administration by intradermal tattooing and its efﬁcacy in
inducing a speciﬁc T cell immune response. Besides stability,
the inﬂuence of different disaccharides on the transfection
efﬁciency of pDNAwas determined.
MATERIALS AND METHODS
Chemicals
The insert of the pVAX-based plasmid pDERMATT
(Fig. 1; 3.8 kb) was designed at The Netherlands Cancer
Institute (NKI-AvL, Amsterdam, The Netherlands). pDER-
MATT and the reporter plasmid pVAX:Luc (4.7 kb) were
produced in-house (AmBTU, Amsterdam, The Netherlands;
23). Sucrose and lactose (Ph. Eur. Grade) were purchased
from BUFA (Uitgeest, The Netherlands). Trehalose, maltose
(both highly pure ≥99.0%), Tris, NaCl and water for
chromatography were obtained from Merck (Darmstadt,
Germany). Sterile water for injections was purchased from
B. Braun (Melsungen, Germany). Isopropanol and 25% (w/v)
HCl were obtained from Biosolve B.V. (Amsterdam, The
Netherlands). All chemicals obtained were of analytical grade
and used without further puriﬁcation.
High Pressure Liquid Chromatography
pDERMATT purity was determined using a validated
anion-exchange (AEX)-high pressure liquid chromatography
(HPLC) system, with a TSKgel DNA-NPR column
(75 mm × 4.6 mm I.D. particle size 2.5µm, Anachem House,
Luton, England) and linear NaCl gradient from 0.45–0.53 M
(A: 20 mM tris, pH9.0 in 10% IPA; B: 20 mM tris, 1 M NaCl,
pH9.0 in 10% IPA), as described previously (24).
Pharmaceutical Formulation Development
Differential Scanning Calorimetry
Glass transition temperatures (Tg) of pDERMATT
formulations were determined using a Q2000 DSC equipped
with a refrigerated cooling accessory for low temperature in
the T4P mode (TA Instruments, New Castle, DE, USA).
Temperature scale and heat ﬂow were calibrated with indium.
Approximately 5 mg of lyophilised product was transferred
into Tzero Aluminium pans, hermetically closed, equilibrated
at −40°C and heated to 70°C or 120°C with 2°C/min and
1°C/min modulation for partly wet or fully dried formulations,
respectively. An empty pan was used as reference.
Manufacture and Stability
Formulation solutions with four disaccharides (sucrose,
trehalose, maltose or lactose) were prepared. Each formula-
tion solution contained 1 mg/ml pDERMATT and 20 mg/ml
disaccharide (corresponding to an excipient/DNA ratio of
20 w/w). Reconstitution with ﬁve times smaller volume
gives an isotonic sucrose solution containing 5 mg/ml
pDERMATT (concentration requested for the phase I
clinical trial). Aliquots of 2 ml were ﬁlled into 8 ml
colourless glass vials (hydrolytic class type 1 Fiolax clear,
Münnerstadter Glaswarenfabrik, Münnerstadt, Germany).
The vials were partly closed with grey butyl rubber lyophilisa-
tion closures (Type FM157/1, Helvoet Pharma N.V., Alken,
Belgium) and loaded into the freeze dryer (Model Lyovac
GT4, GEA Lyophil GmbH, Hürth, Germany). Vials were
frozen to −35°C in 2 h. Primary drying (50 h) was started at a
shelf temperature of −35°C and a chamber pressure of
0.4 mbar. During the primary drying phase temperature was
elevated to −12°C (after 1 h the temperature is linearly
increased to −25°C in 6 h, this temperature was maintained for
38 h after which the temperature is linearly increased to −12°C
in 5 h). Secondary drying (10 h) was carried out at a shelf
temperature of 25°C and a chamber pressure of 0.2 mbar. All
vialswereclosed pneumaticallyundervacuum.Halftheamount
of vials(thefully dried (FD) formulations)weredirectly capped
with ﬂip-off caps (West Pharmaceutical, Germany) and placed
into 25°C/60% RH and 40°C/75% RH climate chambers
(HEKK 0057, Weiss Technik ltd., Buckinghamshire, UK). The
remainder of the vials were weighed, opened and placed into
the 25°C/60% RH climate chamber. After 1 h of incubation the
vials were removed, closed, cappedwith ﬂip-off caps and placed
into theclimatechambersfortheaccelerated stability study (the
Fig. 1. Plasmid DNA map of pDERMATT (plasmid DNA encoding
recombinant MART-1 and tetanus toxin fragment-c) including
selected restriction sites
345 Lyophilisation of Naked pDNA with Disaccharidespartly wet (PW) formulations). FD and PW samples were
analyzed after 1, 3 and 6 months of storage with HPLC and
AGE analysis to determine the stability of the freeze-dried
ﬁnished product.
Residual Water Determination
The residual water content was determined using a stand-
ard Karl Fischer titration. The cake was dissolved in water free
methanol and transferred into the reaction vessel (N=3).
Transfection Efficiency
Tattooing of Ex Vivo Human Skin
Healthy human abdominal skin from female patients was
obtained from the plastic surgery department, according to
institutional guidelines. Subcutaneous fat was directly
removedbybluntdissection. pVAX:Luc disaccharidesolutions
were administered into the intact skin, within 2 h after surgical
removal, by DNA tattooing to allow longitudinal luciferase
expression measurements. This skin model was described
before for the optimization of tattooing of naked DNA in skin
(25). In brief, 10µl of the formulation was appliedonto the skin
into a custom fabricated mould to keep the area of tattooing
constant (diameter 8 mm, surface 50 mm
2). The droplet of
formulation was subsequently administered into skin using a
PMU® tattoo machine (MT Derm GmbH, Berlin, Germany).
For all tattoos, 9-needle cartridges at an oscillating frequency
of 100 Hz were used. The needle depth was adjusted to 1.5 mm
and tattoo duration was 20 s. After tattooing, skin samples
were kept at 5% CO2, 37°C in complete keratinocyte serum-
free medium containing 1% penicillin/streptomycin and
0.25 μg/ml amphotericin B (all Invitrogen). During this
incubation, skin was cultured at the air-medium interface with
the epidermis exposed to the air to mimic the natural situation.
Longitudinal Measurement of Antigen Expression in Human
Skin
The expression of luciferase was measured in intact skin
samples at 3, 18, 24 and 48 h after tattooing. The substrate
luciferin (Xenogen, Hopkinton, MA,USA) was added to the
medium in a ﬁnal concentration of 45 μg/ml. After the
addition of the substrate (30 min), luminescence produced
by active luciferase was acquired during 30 s with an IVIS
system 100 CCD camera (Xenogen, Hopkinton, MA, USA).
Signal intensity was quantiﬁed as the sum of all detected light
within the tattoo area of interest. During each measurement,
background luminescence was measured to allow correction
during data analysis. After each measurement, medium was
refreshed to remove residual luciferin.
Linear Mixed Effect Model
To study the effect of different disaccharides on the level
of antigen (i.e., luciferase) expression, the natural log trans-
form of the area under the curve (AUC) over the 48-h period
was analyzed. To account for possible within skin correlation
of the repeated measurements of antigen expression, a linear
mixed effects model was constructed. The ﬁxed effect was the
solutiontype.Patient identiﬁer was implemented astherandom
grouping variable. Pair-wise interactions were examined
between all ﬁxed effects. The signiﬁcance level was set at 0.05.
Conventional residual analysis was performed to assess model
ﬁt. Data analysis was performed with Splus v6.2 pro (Insightful,
Seattle, WA, USA).
RESULTS
In this study, we used a pDNA formulation at a concen-
tration of 1 mg/ml to which 20 mg/ml of disaccharide was
added. After lyophilisation, this composition enables recon-
stitution of the dried product to an isotonic solution with a ﬁnal
concentration of 5 mg/ml pDNA for intradermal (ID) adminis-
tration. The resulting disaccharide/DNA w/w ratio of 20 in the
formulation solution is much lower than ratios reported in
literature concerning pDNA stabilisation upon lyophilisation,
which rangefrom 100to 4,000(4,7).It wasfoundthat the levels
of disaccharides needed for stability result in hypertonic
solutions upon rehydration that are not compatible with
parenteral (e.g., SC, IM, ID) injection. These studies, however,
focused on non-viral pDNA carriers instead of naked pDNA
for which stabilisation and prevention of aggregation of
particles is of additional importance. Another major difference
in our study is the signiﬁcantly higher DNA starting concen-
tration (e.g., 1 mg/ml vs 20µg/ml (4)).
Formulation Glass Transitions
The disaccharide formulation solutions gave a Tg´
between −32°C and −34°C, which is comparable to literature
(26–29). Furthermore the presence of pDNA had very little
inﬂuence on the Tg´ (data not shown). This ﬁnding is in
contrast to data shown by Jameel et al., where oligonucleo-
tides increase the Tg´ of lactose (30). Consequently, we
lyophilised all formulations using the same lyophilisation
cycle, resulting in a residual water content of approximately
0.8% (w/w) for the FD formulations (Table I). The Tg values
show slightly lower values compared to data reported in
literature (31). This is likely due to the slightly higher residual
moisture content of the pDNA formulations. Additionally,
pDNA itself possibly affects Tg temperatures as well, since
the Tg values of multi-component systems show large
variations as reported earlier for protein formulations (31).
Table I. Tg and Moisture Content of Freeze-dried pDERMATT
Formulations
Formulation Tg of formulation (°C)
Moisture content
(%, w/w)
Fully dried
Trehalose 80.5 0.8 (± 0.04)
Lactose 67.6 0.8 (± 0.05)
Maltose 66.1 0.8 (± 0.07)
Sucrose 45.8 0.8 (± 0.08)
Partly wet (1 h
25°C/60% RH)
Trehalose 26.1 10.0 (± 0.16)
Lactose 32.6 8.6 (± 0.24)
Maltose 20.5 7.5 (± 0.13)
Sucrose 10.8 8.4 (± 0.40)
346 Quaak, Haanen, Beijnen and NuijenConsistent with literature, trehalose displayed the highest Tg,
followed by lactose, maltose and sucrose. The moisture
contents of the PW formulations were in the range between
7.5% and 10.0% (w/w). As expected, these moisture contents
resulted in markedly lower Tg temperatures (Table I). Again,
the trehalose, maltose and lactose formulations had a higher
Tg than the sucrose formulation.
Accelerated Stability Study of Lyophilised Formulations
Figure 2 shows the SC purity of the FD and PW
formulations after storage at the two different storage
conditions. In the FD formulations all disaccharides were
able to keep the SC purity well above 90% during storage for
at least 6 months at 25°C/60% RH (Fig. 2a). However, when
Table II. Visual Observation of PW pDERMATT Formulations (1 h 25°C/60% RH) Stored at Various Temperatures and Relative Humidity;
FD pDERMATT Formulations Stored at Both Storage Conditions Showed no Collapse for Either Disaccharide
Storage condition/formulation
Visual observation after storage
t=0 t=1 month t=3 months t=6 months
25°C/60% RH
Trehalose ----
Lactose ----
Maltose - Partial collapse Partial collapse Partial collapse
Sucrose Partial collapse Collapse Collapse Collapse
40°C/75% RH
Trehalose - - - Partial collapse
Lactose - Collapse Collapse Collapse
Maltose - Collapse Collapse Collapse
Sucrose Partial collapse Collapse Collapse Collapse
Fig. 2. Purity of pDERMATT lyophilised with four different disaccharides (filled circles represent sucrose; filled nabla
represents trehalose; circles represent maltose; triangles represent lactose) fully dried (a,b) and partly wet (c,d) after storage
at 25°C/60% RH (a,c) and 40°C/75% RH (b,d)
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levels signiﬁcantly drop with sucrose and trehalose perform-
ing best with approximately 80% SC remaining after 6 months
of storage (Fig. 2b). None of the FD formulations showed
collapse at either storage condition, in contrast to the PW
formulations. As expected, due to its low Tg temperature
sucrose formulations readily collapsed at both storage con-
ditions (Table II), and with this collapse SC purity dramati-
cally decreased (Fig. 2c,d). Although the maltose
formulations at 25°C/60% RH showed partial collapse SC
purity was not affected. Trehalose and lactose were able to
maintain the cake structure and SC purity at this storage
temperature. However when the PW formulations are stored
at 40°C/75% RH, SC purity decreases rapidly in all formu-
lations (Fig. 2d), although the trehalose formulation main-
tained cake structure up to 6 months of storage. Upon
degradation, SC pDNA is initially mainly converted to OC
pDNA as exempliﬁed for sucrose in Fig. 3. This DNA then
degrades over time in smaller oligonucleotides appearing in
the ﬂow through with HPLC analysis or as a smear in AGE
analysis (data not shown).
Luciferase Expression with Addition of Disaccharides
To assess the effect of excipients on antigen expression,
solutions of a reporter plasmid (pVAX:Luc) 100% SC
containing 10% (w/v) of one of the disaccharides were
applied to ex vivo human skin (25). Interestingly, pDNA
without any excipients gave a signiﬁcantly higher antigen
expression (higher AUC) than when lyoprotectants are
added to the formulation (all p values<0.01). Figure 4 shows
the decrease in AUC for each disaccharide compared to
pDNA dissolved in WfI. When comparing the disaccharides
amongst each other, maltose performed signiﬁcantly better
than trehalose (p=0.001) or lactose (p=0.01). Between
sucrose and the other disaccharides there were no signiﬁcant
differences in performance. A decrease in SC purity to 75%
showed that expression is related to the SC purity rather than
the disaccharide that was used in the formulation solution
(data not shown).
DISCUSSION AND CONCLUSION
This accelerated stability study shows that the pDNA
vaccine pDERMATT can be efﬁciently protected using
disaccharides in a ratio of 20 w/w. At a storage condition of
25°C/60% RH no degradation of pDERMATT could be
observed for at least 6 months of storage, irrespective of the
disaccharide used. Even for the PW formulations, simulating
the increase in moisture content of lyophilised formulations
upon storage, no decrease in SC content could be observed
with the exception of the sucrose-based formulation. It may be
argued, however, that the induced moisture levels of 7.5–10%
Fig. 4. Decrease in Ln(AUC) of luciferase expression (photons/s) in
human ex vivo skin after tattoo administration (2 mg/ml pVAX:Luc,
needle depth 1.5 mm, 100 Hz, 20 s) when formulated in disaccharides
vs dissolved in water. pDNA dissolved in water without any
excipients gave a signiﬁcant better expression (Ln(AUC)=15.6) than
when disaccharides are added to the formulation (all p values <0.01).
Of the tested disaccharides only maltose gave a signiﬁcant better
expression than trehalose (p value 0.001) and lactose (p value 0.01).
Maltose compared to sucrose gave a p value of 0.104
Table III. Stability of pDERMATT 2 mg/Vial Lyophilised in 20 mg/ml
Sucrose after Storage at 2–8°C
Storage time
(months) Content (%) SC Purity (%)
Residual
moisture (%)
0 99.6 98.4 0.7 (± 0.07)
3 98.0 98.5 nd
6 100.8 96.2 1.96 (± 0.51)
9 98.7 96.9 nd
12 98.4 96.3 2.20 (± 0.01)
18 96.9 97.4 nd
24 97.4 99.0 2.39 (± 0.09)
nd not determined
Fig. 3. Representative chromatograms of pDERMATT in sucrose
(PW) during storage at 40°C/75% RH; at t=0(a), t=1 month (b)a n d
t=6 months (c). 1µg injection, detection at 260 nm
348 Quaak, Haanen, Beijnen and Nuijenof the PW formulations are high and will very likely not be
reachedduringshelf life under commonpharmaceutical storage
conditions. Only when stored at a higher temperature (40°C/
75% RH) and moreover in combination with high moisture
levels rapid and signiﬁcant reduction of SC content occurs. The
poor storage stability of PW sucrose may be due to crystal-
lisationofthesugar.Sucroseisknowntocrystallisereadilywhen
stored at temperatures above its Tg (32,33) and crystallisation is
associated with moisture desorption (34). In fact, it has been
shown that lyophilised sucrose shows moisture sorption fol-
lowed by desorption when stored at relative humidities ranging
from 33–80% for a prolonged period oftime (34,35).Crystalline
sucrose is anhydrous, therefore the water content of the
remaining amorphous phase increases and its Tg decreases
(19). With a decrease in Tg, the crystallisation temperature also
decreases from 125°C at 0.8% residual water to 65°C at 8.4%
residual water, as is comparable to data reported by Saleki-
Gerhardt (32). This apparent paradox in Tg temperature and
structure preservation has been reported previously (9,18,36).
Even though sucrose has the lowest Tg temperature it does give
the lowest aggregation rate (18) or the highest transfection
efﬁciency(9).Itisspeculated thatsucrose mightstabilise pDNA
by directly interacting with pDNA rather than by vitrifying to a
high-Tg solid (9). In lipid/DNA formulations sucrose might
isolate individual particles in the unfrozen fraction during
lyophilisation, thus preventing aggregation and loss of trans-
fection efﬁciency (36). Also the fact that sucrose is a non-
reducing sugar could explain why sucrose is a better protector
during lyophilisation. Since trehalose is also a non-reducing
sugar it is expected that trehalose would have similar protective
propertiestosucroseifthisplaysarole.Itisnotclearwhyduring
accelerated storage maltose and lactose are not as good in
protecting the pDNA structure as sucrose and trehalose,
especially when comparing at 40°C/75% RH (Fig. 2). Maltose
and lactose are both reducing sugars, which could play a role.
Surprisingly, when tattooing the different formulations
into an ex vivo human skin model, the different disaccharides
do affect antigen expression of plasmid DNA, probably as a
result of the higher viscosity of the disaccharide solutions
compared to pure water. Maltose performed better than
trehalose and lactose, but no signiﬁcant difference with
sucrose was found. Furthermore, the differences in antigen
expression are limited (2.8% lower AUC for sucrose than
when dissolved in water), and although a higher antigen
expression is correlated to a higher immune response (37), we
do not expect this to be clinically relevant. In view of this and
the performance of the FD formulation at the 25°C/60% RH
and 40°C/75% RH conditions, sucrose was selected as
lyoprotectant for pDERMATT. To prevent the amorphous
lyophilised formulation from undergoing moisture induced
crystallisation we selected a long-term storage condition of 2–
8°C, well below its Tg value of 46°C (34). Table III shows that
under this storage condition the sucrose-based formulation is
stable for at least 24 months. As expected, residual moisture
content increased only slightly and no physical collapse of the
cake was seen. Currently, stability studies substantiating a
long-term storage condition of 15–25°C are ongoing using a
shelf-life speciﬁcation of ≥80% SC pDNA. We recently
demonstrated that in the range of 100% to 75% SC pDNA
antigen expression drops linearly, but only with 10% (38).
This is due to the fact that OC pDNA, the main degradation
product upon storage, still gives relatively high levels of
antigen expression. In line with this, the US Food and Drug
Agency (FDA) recommends that the fraction of the SC
topoisoform in pDNA vaccines is at least 80% (www.fda.gov/
cber/gdlns/plasdnavac.htm). In conclusion, we have demon-
strated that disaccharides, like sucrose and trehalose, can be
used as naked pDNA lyoprotectants.
ACKNOWLEDGEMENTS
We would like to thank Joost van den Berg of the
Department of Pharmacy and Pharmacology (Slotervaart
Hospital/The Netherlands Cancer Institute, Amsterdam, The
Netherlands) for performing the ex vivo human skin experi-
ments. Andrew Vincent of the Division of Biostatistics (The
Netherlands Cancer Institute, Amsterdam, The Netherlands)
is acknowledged for performing the statistical analysis.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which
permits any noncommercial use, distribution, and reproduction in
any medium, provided the original author(s) and source are
credited.
REFERENCES
1. Schleef M, Schmidt T. Animal-free production of ccc-supercoiled
plasmids for research and clinical applications. J Gene Med.
2004;6 Suppl 1:S45–53.
2. Przybylowski M, Bartido S, Borquez-Ojeda O, Sadelain M,
Riviere I. Production of clinical-grade plasmid DNA for human
Phase I clinical trials and large animal clinical studies. Vaccine.
2007;25(27):5013–24.
3. Walther W, Stein U, Voss C, Schmidt T, Schleef M, Schlag PM.
Stability analysis for long-term storage of naked DNA: impact on
nonviral in vivo gene transfer. Anal Biochem. 2003;318(2):230–5.
4. Anchordoquy TJ, Armstrong TK, Molina MC. Low molecular
weight dextrans stabilize nonviral vectors during lyophilization at
low osmolalities: concentrating suspensions by rehydration to
reduced volumes. J Pharm Sci. 2005;94(6):1226–36.
5. Poxon SW, Hughes JA. The effect of lyophilization on plasmid
DNA activity. Pharm Dev Technol. 2000;5(1):115–22.
6. Levy MS, O'Kennedy RD, Ayazi-Shamlou P, Dunnill P. Bio-
chemical engineering approaches to the challenges of producing
pure plasmid DNA. Trends Biotechnol. 2000;18(7):296–305.
7. Anchordoquy TJ, Armstrong TK, Molina MC, Allison SD, Zhang
Y, Patel MM, et al. Physical stabilization of plasmid DNA-based
therapeutics during freezing and drying. In: Costantino HR, Pikal
MJ, editors. Lyophilization of biopharmaceuticals. AAPS press;
2004. pp. 605–41.
8. Lee SL, Debenedetti PG, Errington JR, Pethica BA, Moore DJ.
A calorimetric and spectroscopic study of DNA at low hydration.
J Phys Chem B. 2004;108:3098–106.
9. Maitani Y, Aso Y, Yamada A, Yoshioka S. Effect of sugars on
storage stability of lyophilized liposome/DNA complexes with
high transfection efﬁciency. Int J Pharm. 2008;356(1–2):69–75.
10. Molina MC, Armstrong TK, Zhang Y, Patel MM, Lentz YK,
Anchordoquy TJ. The stability of lyophilized lipid/DNA com-
plexesduringprolongedstorage.J PharmSci.2004;93(9):2259–73.
11. Anchordoquy TJ, Koe GS. Physical stability of nonviral plasmid-
based therapeutics. J Pharm Sci. 2000;89(3):289–96.
12. Molina MD, Anchordoquy TJ. Formulation strategies to mini-
mize oxidative damage in lyophilized lipid/DNA complexes
during storage. J Pharm Sci. 2008;97(12):5089–105.
13. van Winden E. Freeze-drying of liposomes: a critical review of
mechanisms involved in lyoprotection and solid-state stability. In:
349 Lyophilisation of Naked pDNA with DisaccharidesCostantino HR, Pikal MJ, editors. Lyophilization of biopharma-
ceuticals. AAPS press; 2004. pp. 563–604.
14. Szoka F, Wang J. The regents of the University of California,
editor. Stabilized polynucleotide complexes and methods. Oak-
land, CA (US) patent US 7,323,297 BI. 2008.
15. Allison SD, Anchordoquy TJ. Mechanisms of protection of
cationic lipid-DNA complexes during lyophilization. J Pharm Sci.
2000;89(5):682–91.
16. Hinrichs WL, Sanders NN, De Smedt SC, Demeester J, Frijlink
HW. Inulin is a promising cryo- and lyoprotectant for PEGylated
lipoplexes. J Control Release. 2005;103(2):465–79.
17. Ando S, Putnam D, Pack DW, Langer R. PLGA microspheres
containing plasmid DNA: preservation of supercoiled DNA via
cryopreparation and carbohydrate stabilization. J Pharm Sci.
1999;88(1):126–30.
18. Chang LL, Shepherd D, Sun J, Ouellette D, Grant KL, Tang XC,
et al. Mechanism of protein stabilization by sugars during freeze-
drying and storage: native structure preservation, speciﬁc
interaction, and/or immobilization in a glassy matrix? J Pharm
Sci. 2005;94(7):1427–44.
19. Kreilgaard L, Frokjaer S, Flink JM, Randolph TW, Carpenter JF.
Effects of additives on the stability of recombinant human factor
XIII during freeze-drying and storage in the dried solid. Arch
Biochem Biophys. 1998;360(1):121–34.
20. Kendrick BS, Chang BS, Arakawa T, Peterson B, Randolph TW,
Manning MC, et al. Preferential exclusion of sucrose from
recombinant interleukin-1 receptor antagonist: role in restricted
conformational mobility and compaction of native state. Proc
Natl Acad Sci USA. 1997;94(22):11917–22.
21. Sharma VK, Klibanov AM. Moisture-induced aggregation of
lyophilized DNA and its prevention. Pharm Res. 2007;24(1):168–75.
22. Shamblin S. The role of water in physical transformations in
freeze-dried products. In: Costantino HR, Pikal MJ, editors.
Lyophilization of biopharmaceuticals. Arlington, VA: AAPS;
2004. p. 229–70.
23. Quaak SGL, Berg JH, Toebes M, Schumacher T, Beijnen JH,
Nuijen B. GMP production of pDERMATT for vaccination
against melanoma in a phase I clinical trial. Eur J Pharm
Biopharm. 2008;70(2):429–38.
24. Quaak SGL, Nuijen B, Haanen JB, Beijnen JH. Development
and validation of an LC-UV method for the quantiﬁcation and
purity determination of pDERMATT. J Pharm Biomed Anal.
2009;49(2):282–8.
25. van den Berg JH, Nuijen B, Beijnen JH, Vincent A, Van Tinteren
H, Kluge J, et al. Optimization of intradermal vaccination by DNA
tattooing in human skin. Hum Gene Ther. 2009;20(3):181–9.
26. Oesterle J, Franks F, Auffret T. The inﬂuence of tertiary butyl
alcohol and volatile salts on the sublimation of ice from frozen
sucrose solutions: implications for freeze-drying. Pharm Dev
Technol. 1998;3(2):175–83.
27. Costantino HR. Exipients for use in lyophilized pharmaceutical
peptide, protein and other bioproducts. In: Costantino HR, Pikal
MJ, editors. Lyophilization of biopharmaceuticals. Arlington,
VA: AAPS; 2004. p. 139–228.
28. Van Drooge DJ, Hinrichs WL, Frijlink HW. Incorporation of
lipophilic drugs in sugar glasses by lyophilization using a mixture
of water and tertiary butyl alcohol as solvent. J Pharm Sci.
2004;93(3):713–25.
29. Tang X, Pikal MJ. Design of freeze-drying processes for
pharmaceuticals: practical advice. Pharm Res. 2004;21(2):191–
200.
30. Jameel F, Amsberry KL, Pikal MJ. Freeze drying properties of
some oligonucleotides. Pharm Dev Technol. 2001;6(2):151–7.
31. Kawai K, Suzuki T. Stabilizing effect of four types of disacchar-
ide on the enzymatic activity of freeze-dried lactate dehydrogen-
ase: step by step evaluation from freezing to storage. Pharm Res.
2007;24(10):1883–90.
32. Saleki-Gerhardt A, Zograﬁ G. Non-isothermal and isothermal
crystallization of sucrose from the amorphous state. Pharm Res.
1994;11(8):1166–73.
33. Sarciaux JM, Hageman MJ. Effects of bovine somatotropin
(rbSt) concentration at different moisture levels on the physical
stability of sucrose in freeze-dried rbSt/sucrose mixtures. J
Pharm Sci. 1997;86(3):365–71.
34. Yu X, Kappes SM, Bello-Perez LA, Schmidt SJ. Investigating the
moisture sorption behavior of amorphous sucrose using a
dynamic humidity generating instrument. J Food Sci. 2008;73
(1):E25–35.
35. Carstensen JT, Van Scoik K. Amorphous-to-crystalline trans-
formation of sucrose. Pharm Res. 1990;7(12):1278–81.
36. Allison SD, Molina MC, Anchordoquy TJ. Stabilization of lipid/
DNA complexes during the freezing step of the lyophilization
process: the particle isolation hypothesis. Biochim Biophys Acta.
2000;1468(1–2):127–38.
37. Bins AD, Jorritsma A, Wolkers MC, Hung CF, Wu TC,
Schumacher TN, et al. A rapid and potent DNA vaccination
strategy deﬁned by in vivo monitoring of antigen expression. Nat
Med. 2005;11(8):899–904.
38. Quaak SGL, Berg JH, Beijnen JH, Haanen J, Nuijen B. DNA
tattoo vaccination: effect on plasmid purity and transfection
efﬁciency of different topoisoforms. J Control Release. 2009;139
(2):153–9.
350 Quaak, Haanen, Beijnen and Nuijen